Design and synthesis of spiroketal analogs of didemnaketal A and B

ORGN 655

Xiaodong Fan, xfan@atherogenics.com, Medicinal Chemistry, AtheroGenics, Inc, 8995 Westside Parkway, Alpharetta, GA 30004 and Daniel H. Rich, dhrich@wisc.edu, School of Pharmacy & Department of Chemistry, University of Wisconsin-Madison, 7109 Rennebohm Hall, 777 Highland Ave, Madison, WI 53705.
The Didemnaketal A and B (1a,b) inhibit HIV protease with IC50s of 2 mM and 10 mM, respectively, and are early examples of HIV protease inhibitors that lack nitrogen (see, Fan, X., et al, J. Am. Chem. Soc. 1998, 120, 8893). In the course of determining the key portion of these compounds that inhibits the protease, we synthesized a series of spiroketal structures 2 and 3. Two series of compounds with C11 to C21 and C8 to C21 subunit were included as synthetic targets. The HIV-1 protease assay indicated that these spiroketal analogs do not inhibit HIV protease. Synthetic efforts toward the spiroketal analogs 2-3 will be presented.